In another reversal, FDA gives uniQure accelerated approval path for Huntington's gene therapy on June 18, 2026 Accelerated AMT-130 Approved Biologics License Application Breakthrough Therapy cUHDRS gene therapy Huntington 's disease NEFL gene Phase I/II study RMAT uniQure United States Food and Drug Administration +